PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
González-Woge, M.* ; Contreras-Espinosa, L.* ; García-Gordillo, J.A.* ; Aguilar-Villanueva, S.* ; Bargallo-Rocha, E.* ; Cabrera-Galeana, P.* ; Vasquez-Mata, T.* ; Cervantes-López, X.* ; Vargas-Lías, D.S.* ; Montiel-Manríquez, R.* ; Bautista-Hinojosa, L.* ; Rebollar-Vega, R.* ; Castro-Hernández, C.* ; Álvarez-Gómez, R.M.* ; De La Rosa Velázquez, I.A. ; Díaz-Chávez, J.* ; Jiménez-Trejo, F.* ; Arriaga-Canon, C.* ; Herrera, L.A.*

The expression profiles of lncRNAs are associated with neoadjuvant chemotherapy resistance in locally advanced, luminal B-type breast cancer.

Int. J. Mol. Sci. 25:8077 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
lncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, lncRNAs exhibit subtype-specific expression; they are particularly upregulated in luminal tumors. However, no gene signature-based laboratory tests have been developed for luminal breast cancer identification or the differential diagnosis of luminal tumors, since no luminal A- or B-specific genes have been identified. Particularly, luminal B patients are of clinical interest, since they have the most variable response to neoadjuvant treatment; thus, it is necessary to develop diagnostic and predictive biomarkers for these patients to optimize treatment decision-making and improve treatment quality. In this study, we analyzed the lncRNA expression profiles of breast cancer cell lines and patient tumor samples from RNA-Seq data to identify an lncRNA signature specific for luminal phenotypes. We identified an lncRNA signature consisting of LINC01016, GATA3-AS1, MAPT-IT1, and DSCAM-AS1 that exhibits luminal subtype-specific expression; among these lncRNAs, GATA3-AS1 is associated with the presence of residual disease (Wilcoxon test, p < 0.05), which is related to neoadjuvant chemotherapy resistance in luminal B breast cancer patients. Furthermore, analysis of GATA3-AS1 expression using RNA in situ hybridization (RNA ISH) demonstrated that this lncRNA is detectable in histological slides. Similar to estrogen receptors and Ki67, both commonly detected biomarkers, GATA3-AS1 proves to be a suitable predictive biomarker for clinical application in breast cancer laboratory tests.
Impact Factor
Scopus SNIP
Altmetric
4.900
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Breast Cancer ; Lncrna ; Luminal B ; Neoadjuvant Chemotherapy ; Predictive Biomarker ; Transcriptome; In-situ Hybridization; Treatment Decisions; Survival; Ki-67; Estrogen; Receptor; Index; Ihc
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 1661-6596
e-ISSN 1422-0067
Zeitschrift International Journal of Molecular Sciences
Quellenangaben Band: 25, Heft: 15, Seiten: , Artikelnummer: 8077 Supplement: ,
Verlag MDPI
Verlagsort Basel
Begutachtungsstatus Peer reviewed
Institut(e) CF Genomics (CF-GEN)
POF Topic(s) 30501 - Systemic Analysis of Genetic and Environmental Factors that Impact Health
PSP-Element(e) A-632700-001
Förderungen Curriculum Vitae nico
CONACYT
Consejo Nacional de Ciencia, Humanidades y Tecnologia (CONAHCYT)
National Cancer Institute of Mexico
DOI 10.3390/ijms25158077
WOS ID 001287797100001
Scopus ID 85201008264
PubMed ID 39125649
Erfassungsdatum 2024-09-30
[➜Korrektur melden]